免疫治疗在复发/难治性急性B淋巴细胞白血病中的应用
x

请在关注微信后,向客服人员索取文件

篇名: 免疫治疗在复发/难治性急性B淋巴细胞白血病中的应用
TITLE: Application of immunotherapy in relapsed/refractory B-cell acute lymphoblastic leukemia
摘要: 免疫治疗作为一种新兴的治疗方法,被证实能够改善复发/难治性急性B淋巴细胞白血病(B-ALL)患者的预后,具有良好的应用前景。其中,嵌合抗原受体修饰的T细胞免疫疗法(CAR-T)和单克隆抗体免疫疗法显示出巨大的应用潜力,多款药物已被批准上市。本文对上述两种疗法治疗复发/难治性B-ALL的临床应用情况进行归纳总结,得出CAR-T是一种个体化免疫疗法,理想靶标的选择是其发挥作用的重要环节,目前其临床研究中理想的靶点包括CD19、CD22、CD19/CD22;单克隆抗体主要包括博纳吐单抗和奥加伊妥珠单抗,其对复发/难治性B-ALL显示出良好的疗效。免疫治疗比常规化疗显示出更优异的治疗效果,拓宽了复发/难治性B-ALL治疗方案的选择面。
ABSTRACT: Immunotherapy, as an emerging treatment method, has been proven to improve the prognosis of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and has good application prospects. Immunotherapy, including chimeric antigen receptor T cell immunotherapy (CAR-T) and monoclonal antibodies, has shown great potential for application, and has been approved for marketing. This article summarizes the application of the above two therapies in the treatment of relapsed/ refractory B-ALL, and concludes that CAR-T is a kind of personalized immunotherapy, and the selection of ideal targets is an important part of its action. Currently, the ideal targets in clinical studies include CD19, CD22 and CD19/CD22. Monoclonal antibodies, including blinatumomab and inotuzumab ozogamicin, have shown superior therapeutic efficacy for relapsed/refractory B- ALL. Immunotherapy has shown superior therapeutic effects compared to conventional chemotherapy, expanding the selection of treatment options for relapsed/refractory B-ALL.
期刊: 2024年第35卷第07期
作者: 初琪慧;高彤;曲素欣;闫美兴
AUTHORS: CHU Qihui,GAO Tong,QU Suxin,YAN Meixing
关键字: 复发/难治性急性B淋巴细胞白血病;免疫治疗;CAR-T疗法;单克隆抗体
KEYWORDS: relapsed/refractory B-cell acute lymphoblastic leukemia; immunotherapy; CAR-T therapy; monoclonal antibodies
阅读数: 14 次
本月下载数: 1 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!